Hidradenitis suppurativa/acne inversa is a diverse, enigmatic and distressful disease that has aroused growing interest in specialists from different disciplines. Both names describe its classical manifestations in the intertriginous regions and reflect the historical view of the disease definition, but cause confusions in the understanding of its pathogenesis and classification. In the light of the advance in clinical, histopathological and pathophysiological findings, we propose the term "dissecting terminal hair folliculitis" (DTHF) to characterize its disease nature as folliculitis instead of acneiform disease or apocrine gland disorder. DTHF attacks exclusively the terminal hair follicles in an overwhelming majority of adults, initiating from the fragile acroinfundibulum leading to a non-infectious overreaction of innate immunity system with inflammation that may fiercely dissect and engulf all the surrounding tissues accompanied by secondary bacterial infections. Evidence indicates that perifolliculitis capitis abscedens et suffodiens and pilonidal disease are very likely regional variants of DTHF with the same pathogenesis. Treatment of DTHF remains frustrating. The benefit of biologics in targeting inflammation is so far non-specific, palliative and inconsistent. Hair epilation and photodynamic therapy in treatment of the disease is questionable in consideration of the pathogenesis. Genetic and translational research, especially on the Notch signalling pathways, will yield breakthrough in the development of novel treatment modalities.
V I E W P O I N T
Should hidradenitis suppurativa/acne inversa best be renamed as "dissecting terminal hair folliculitis"? WenChieh Chen 1,2 | Gerd Plewig 3 with the autosomal dominant familial form of HS/AI. [1] In spite of the advance in the understanding of its pathogenesis and publication of many national or international guidelines for disease classification and management (s8,s9), the aetiology of this group of diseases remains incompletely understood, and no standard treatment has been estab- 
| INTRODUCTION: TIMES OF CONFUSION

| ANATOMY, PHYSIOLOGY AND PATHOLOGY
Three kinds of human hair follicles are recognized: sebaceous, vellus and terminal, which differ significantly in their fine structure and distribution. [2] Acne occurs in sebaceous follicles and never in terminal hair follicles. Sebaceous follicles are widely distributed over the entire skin except on the palms and soles. The apocrine sweat glands are mainly found in axillae, pubis, labia majora, scrotum, perineum, perianal regions and areola of the breast, but lacking in other intertriginous regions like submammary, antecubital or popliteal. Unlike eccrine sweat glands, apocrine sweat glands are innervated by the adrenergic nerve fibres, and their long excretory ducts open into the acroinfundibulum of the terminal hair follicles (Fig. S1A ).
The earliest pathologic change of HS/AI was observed in the junction between apocrine sweat duct and terminal hair infundibulum, with two major findings ( Fig. S1B ): (i) microcomedones in the ampulla of the apocrine sweat duct draining into the hair acroinfundibulum; [2] (ii) mild hyperplasia and segmental spongiosis of the epithelium in the acroinfundibulum (Fig. S1C,D) , which is speculated to be caused by the epithelial instability associated with impaired Notch-MKP-1 signalling. [3] It is unclear whether they happen concurrently or which event comes first. The subsequent breakage of the infrainfundibulum with rupture of the follicular epithelium initiates the inflammatory cascade ( Fig. S2A) , sometimes with violent and stormy progression to cause a tsunami-like damage, whereby the apocrine and eccrine sweat glands are passively engulfed by the flooding inflammation rampaging everywhere ( Fig. S2C-E) . At this stage, the sebaceous follicles and sebaceous glands of terminal hair follicles are affected as innocent bystanders. This observation has been shared and supported by many subsequent studies, showing that the terminal hair infundibulum is the primary site of defect. [4] [5] [6] Mechanical stress can act as a possible trigger in the disease development (s10,s11).
It is unclear whether the reduced number and volume of sebaceous glands in uninvolved hair follicles from patients with HS/AI is in a causal link or is the result of a common pathogenic process (s12).
This is observed in the lesions of HS/AI, but does not apply to the uninvolved terminal hair follicles in the unaffected regions of these patients. All terminal hair follicles have more or less attached sebaceous lobules, smaller or bigger in size, which can modulate during the hair cycle. [2] In both human and animals, it is known that with irritation, including inflammation, the sebaceous glands regress in size or virtually disappear temporarily.
| HIDRADENITIS SUPPURATIVA (HS), ACNE INVERSA (AI) AND DISSECTING TERMINAL HAIR FOLLICULITIS (DTHF): THREE NAMES FOR THE SAME DISEASE
Based on the above discussion, one of the authors (GP) first proposed the term dissecting terminal folliculitis in 2009 (s13), now more precisely termed as dissecting terminal hair folliculitis (DTHF), to replace HS and AI. These three synonyms can be redefined as follows: (Fig. S2A,B) . [2] Apocrine sweat glands or sebaceous glands are secondarily attacked. DTHF can be further labelled as axillary, submammary, inguinal, gluteal or facial DTHF, according to the site of involvement.
| CLINICAL IMPACT OF THE REDEFINITIONS
1. Synchrony and metachrony between AC and DTHF: Acne and its massive expression AC usually begin from teenage and most of the patients never develop DTHF later in life. On the other hand, DTHF is a disease of adults and very rare in children, runs relentlessly, often ad infinitum, with most of the patients never experiencing severe acne or AC in early life (Table ST1) .
AC and DTHF do not develop in parallel (no synchrony), but it may start in certain patients initially with AC accompanying puberty, and being attacked by DTHF later (metachrony). The statistics about natural intersection or concurrence of both diseases is unknown. In our own experience, it is uncommon.
Differentiation between DTHF and AC in the regions abundant with both terminal hair and sebaceous follicles can be challenging, such as chest, back and beard. A careful histological examination in the early stage can help.
2.
As compared to AC, the non-hereditary, non-syndromic DTHF affects mainly Caucasian women (female to male ration 3-4 to 1) with a close association with smoking and obesity (s18-s20). The seemingly low prevalence of DTHF in China, [7] Japan (s21), Korea and Taiwan might be explained by a generally lower prevalence of hirsutism, obesity, smoking and the use of contraceptives in women from these regions. Moreover, more men are affected than women in these regions, based on the case series reported to date (s22). (s32-s35). [8] Given the rarity of controlled studies, biologics seem to benefit more the arthritis and pyoderma gangrenosum in diverse associated rare syndromes, their effect on acne is muss less convincing and long-term efficacy remains to be confirmed (s36, s37).
6.
Laser hair epilation has been proposed to be a promising treatment for DTHF, so far with scanty evidence (s38). In theory, therapy should aim to normalize or stabilize the follicular infundibulum but not to inhibit hair growth. Further understanding on the possible working mechanisms of laser treatment is required.
Perifolliculitis capitis abscedens et suffodiens (Hoffmann disease)
and pilonidal disease both share many clinical, histological and immunohistological characteristics with DTHF (s39). [9] Many similarities also exist in their treatment options and disease course.
They are definitely the disease of terminal hair follicles in the category of "folliculitis" and no longer belong to acne based on the redefinition.
| CONCLUSION
Terminal hair follicles and sebaceous follicles are two different hair follicles of distinctive natures. In pathophysiology, DTHF is neither hidradenitis nor acne; instead, it is folliculitis of terminal hair follicles.
Inconsistency The proposal of DTHF will pave and lead the way for a better understanding of pathogenesis and future design of novel treatment modalities.
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